The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.50
Bid: 95.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 5.00 (5.263%)
Open: 97.50
High: 97.50
Low: 97.50
Prev. Close: 97.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa - revolutionising clinical messaging

26 Jul 2019 12:03

RNS Number : 8929G
Feedback PLC
26 July 2019
 

 

Feedback plc

 

BleepaTM - revolutionising clinical messaging

 

New medical grade imaging app to be launched at NHS Expo on 4-5 September 2019

 

Cambridge, 26 July 2019: Further to the Company's strategic review announcement on 10 July 2019, Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today provides an update on its new clinical messaging product: BleepaTM.

 

As previously announced, Feedback plans to establish a leading role in the medical communication market. BleepaTM, its new app for clinicians, is currently in beta development and will be formally launched at NHS Expo on 4-5 September 2019 in Manchester.

 

Based on Feedback's Cadran technology, BleepaTM is a secure, encrypted medical communication tool accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). BleepaTM enables faster clinical decision making between team members wherever they are, accelerating and improving patient care.

 

According to an article published in BMJ Innovations, 97% of hospital doctors routinely use WhatsApp to communicate about patients.1

 

This increasing trend for clinicians to use personal devices to discuss patient care and make clinical decisions is more convenient and efficient than traditional methods of clinical communication. However, using such methods opens doctors and their patients up to a variety of risks.

 

BleepaTM addresses growing concerns about these messaging platforms not meeting diagnostics clinical standards and regarding patient data protection. Continued use of non-specialist communication tools could leave both hospitals and individual clinical users significantly exposed and therefore open to the risk of litigation.

 

The Directors believe BleepaTM will be the only communication tool to be a CE marked medical device. More information can be found at www.bleepa.com.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"We are making rapid progress in the development of our new messaging app, BleepaTM. We believe that it will provide a flexible, accurate and secure method for swift clinical decision making, revolutionising the way in which patients receive treatment whilst safeguarding our doctors from potential litigation. We look forward to showcasing the finished product this September at NHS Expo in Manchester."

 

1 O'Sullivan DM, O'Sullivan E, O'Connor M, et al WhatsApp Doc? BMJ Innovations 2017;3:238-239.

 

-Ends-

Enquiries:

 

Feedback plc

+44 (0)1954 718072

Tom Oakley, CEO

IR@fbk.com

Lindsay Melvin, CFO

 

Instinctif Partners

+44 207 457 2020

Rozi Morris/Phillip Marriage

Feedbackplc@instinctif.com

 

Notes to editors About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFQLFLKDFBBBF
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.